1Durongpisitkul K,Soongswang J,Laohaprasitiporn D,Nana A,Prachuabmoh C,Kangkagate C.Immunoglobulin failure and re-treatment in Kawasaki disease[J].Pediatr Cardiol,2003,24(2):145-148.
2Sittiwangkul R,Pongprot Y,Silvilairat S,Phornphutkul C.Man-agement and outcome of intravenous gammaglobulin-resistant Ka-wasaki disease[J].Singapore Med J,2006,47(9):780-784.
3Brogan PA,Bose A,Burgner D,Shingadia D,Tulloh R,Michie C,et al.Kawasaki disease:an evidence based approach to diag-nosis,treatment,and proposals for future research[J].Arch Dis Child,2002,86(4):286-290.
4Minami T,Suzuki H,Takeuchi T,Uemura S,Sugatani J,Y0-shikawa N.A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treat-ment in Kawasaki disease[J].J Pediatr,2005,147(1):78-83.
10Okada K,Hara J,Maki I,Miki K,Matsuzaki K,Matsuoka T,et al.Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease[J].Eur J Pediatr,2009,168(2):181-185.
二级参考文献28
1Lazarus M, Hajeer AH, Turner D, et al. Genetic variation in the interleukin 10 8ene promoter and systemic lupus erythematosus.J Rheumatol, 1997, 24:2314-2317.
2Hurme M, Lahdenpohja N, Santtila S. Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med, 1998.30:469-473.
3Kamizono S, Yamada A, Higuchi T,et al. Analysis of tumor necrosis factor-alpha production and polymorphisms of the tumor necrosis factor-alpha gene in individuals with a history of Kawasaki disease.Pediatr Int, 1999,41:341-345.
4Quasney MW, Brornstein DE, Cantor RM, et al. Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with kawasaki disease. Pediatr Res , 2001,49:686-690.
5Mok CC, Lanchbury JS, Chan DW, et al. Interleukin-10 promoter polymorphism in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum, 1998,41:1090-1095.
6Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor interleukin 2 receptor, and intederon-ganuna in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopsathol, 1990, 56:29-36.
7Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr, 1996,128:146-149.
8Louis E, Franchimont D, Piton A, et al. Tumor necrosis factor(TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 1998,113,401-406.
9Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol, 1997,34:391-399.
10D′ Alfonso S, Rampi M, Bocchio D, et al. Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum, 2000,43 : 120-128.
9Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease : a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [J]. Pediatrics, 2004, 114(6) : 1708-1733.
10Lee TJ, Kim KH, Chun JK, et al. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant kawasaki disease [J]. Yonsei Med J,2008,49(5) :714-718.
